# A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

> **NCT02842827** · PHASE1,PHASE2 · COMPLETED · sponsor: **Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)** · enrollment: 45 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** bomedemstat
- **DRUG:** tretinoin

## Key facts

- **NCT ID:** NCT02842827
- **Lead sponsor:** Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-06
- **Primary completion:** 2018-10-30
- **Final completion:** 2018-10-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02842827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02842827, "A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02842827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*